Bristol-Myers to buy RayzeBio for $4.1 billion

Bristol-Myers Squibb Company announced on Tuesday in a statement that it has struck a definitive merger deal with RayzeBio, Inc. worth $4.1 billion or $62.50 per share in cash. The boards of directors…